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Objective: Brain-derived neurotrophic factor (BDNF) plays an important role in cell survival, differentiation, and cell death as 
well as in neural plasticity. Recent studies have suggested that BDNF is involved in the pathogenesis of bipolar disorder. The 
aim of this study was to investigate the association of the genetic variations of the BDNF gene with bipolar disorder in Korea. 
We also studied the possible association of these genetic variants with clinical features.
Methods: The allelic and genotypic distributions of Val66Met polymorphism of the BDNF gene were analyzed using a polymerase 
chain reaction-based method in 184 bipolar patients and 214 controls. Analysis was performed to investigate an association 
of the Val66Met polymorphism of the BDNF gene and the clinical features in bipolar patients.
Results: No significant difference was found between bipolar patients and controls in the genotype and allele frequencies for 
the investigated BDNF polymorphism. However, the age of onset of bipolar disorder among the Val/Val (25.57), Val/Met (30.42) 
and Met/Met (32.45) genotype groups were significantly different (p=0.037).
Conclusion: This study suggests that Val66Met polymorphisms are unlikely to contribution to the genetic predisposition to bipolar 
disorder as a whole. But Val66Met polymorphism may be associated with age of onset of the disorder, further studies designed 
to investigate the relationship in a larger population may be warranted.
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INTRODUCTION
Brain-derived neurotrophic factor (BDNF) is involved 
in cell differentiation, cell survival, and cell death,1) as 
well as in overall central nervous system development.2,3) 
BDNF plays an important role in the maintenance of neu-
roplasticity and regulates neurotransmitter synthesis and 
synaptic activity.4-6)
There is growing evidence that BDNF is involved in the 
pathophysiology of bipolar disorder. It has been reported 
to be a target for the action of mood-stabilizing agents and 
antidepressants.7-13) Chen et al.8) reported that levels of 
BDNF immunoreactivity were increased in postmortem 
hippocampal tissue among antidepressant-treated bipolar 
patients compared with antidepressant-untreated bipolar 
patients. In animal models, chronic administration of 
mood stabilizers was shown to up-regulate BDNF ex-
pression levels in rat frontal cortex.14) In addition, neuro-
imaging studies have demonstrated that decreased BDNF 
levels could explain the structural brain changes observed 
in bipolar patients.15)
A polymorphism that results in an amino-acid sub-
stitution of methionine for valine at codon 66 (Val66Met) 
of the BDNF gene may alter intracellular trafficking and 
regulated secretion of BDNF.16) Two family-based studies 
involving relatively large samples found a significant as-
sociation between this Val66Met polymorphism of BDNF 
and bipolar disorder.17,18) Both studies reported over-
transmission of the common Val allele to patients with bi-
polar disorder. In contrast, several studies have failed to 
confirm this association between BDNF and bipolar 
disorder.19-21) In the Asian population in particular, there is 
no evidence for an allelic or genotypic association be-
tween Val66Met and bipolar disorders.22-24)
The Val66Met polymorphism of BDNF may not play a 
major role in influencing susceptibility to bipolar disorder, 
but it may play a role in the specific clinical bipolar 
phenotype. For example, it has been shown that the 
Val66Met polymorphism of BDNF is associated with the 
suicidal behaviors of bipolar patients25) and with rapid 
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cycling.26,27) Several researchers have also studied the as-
sociation between BDNF and childhood-onset bipolar 
disorder.28,29)
We performed this study to test whether the Val66Met 
polymorphism of BDNF is associated with bipolar dis-
order in Korean subjects. We also examined the role of this 
polymorphism, if any, in specific clinical features that 
commonly present in bipolar disorder.
METHODS
Subjects
A total of 184 Korean bipolar patients participated in 
this study. Patients were recruited from the Hallym 
University Sacred Heart Hospital, the Severance Mental 
Health Hospital, the Severance Hospital, and the National 
Health Insurance Corporation Ilsan Hospital. Diagnoses 
of bipolar disorder were made by a psychiatrist according 
to the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition.30) Patients with history of seizure 
disorder, significant head trauma, mental retardation, or 
substance abuse (with the exception of alcohol abuse) 
were excluded from the study. The patients comprised 64 
men and 120 women who were 41.5±13.6 years old 
(mean±standard deviation). The control group comprised 
214 healthy college students with no history of psychiatric 
disorders (86 men and 129 women aged 23.7±2.5 years). 
All subjects provided written informed consent to partic-
ipate in the study after they had received a full explanation 
of the aims of the study and the procedures involved. The 
study protocols were approved by the ethics committee of 
each hospital.
Clinical Assessments
We collected clinical information regarding bipolar dis-
order via direct interviews with individual patients and 
family members, and from medical records. Clinical fea-
tures including age at onset, polarity at onset, any psychi-
atric family history, and suicidal history were evaluated.
Genotyping
We used venipuncture to collect blood samples, and 
DNA was isolated using standard techniques. The geno-
typing was screened using a single base primer extension 
assay using ABI PRISM SNaPshot Multiplex kits (ABI, 
Foster City, CA, USA) according to the manufacturer’s 
recommendations. Briefly, the genomic DNA flanking the 
single-nucleotide polymorphism (SNP) of interest was 
amplified using polymerase chain reaction (PCR) with 
forward primer 5’-TGATGACCATCCTTTTCCTT-3’ 
and reverse primer 5’-CACTGGGAGTTCCAATGC-3’ 
and with standard PCR reagents in a 10 μl reaction vol-
ume containing 10 ng of genomic DNA, 0.5 pM of each 
oligonucleotide primer, 1μl of 10×PCR buffer, 250μM 
dNTP (2.5 mM each), and 0.25 units of i-StarTaq DNA 
Polymerase (5 units/μl; iNtRON Biotechnology, Seong-
nam, Korea). The PCR reactions were carried out as fol-
lows: 1 cycle of 10 min at 95oC; 35 cycles of 95oC for 30 sec, 
55oC for 1 min, and 72oC for 1 min; and 1 cycle of 72oC for 
10 min. After amplification, the PCR products were treat-
ed with 1 unit each of shrimp alkaline phosphatase (SAP; 
Roche, Besel, Switzerland) and exonuclease I (USB 
Corporation, Cleveland, OH, USA) at 37oC for 75 min and 
72oC for 15 min to purify the amplified products. A 1μl 
aliquot of the purified amplification products was added to 
a SNaPshot Multiplex Ready reaction mixture containing 
0.15 pmol of genotyping primer for the primer extension 
reaction. The primer extension reaction was carried out 
for 25 cycles of 96oC for 10 sec, 50oC for 5 sec, and 60oC 
for 30 sec. The reaction products were treated with 1 unit 
of SAP at 37oC for 1 hr and 72oC for 15 min to remove ex-
cess fluorescent dye terminators. A 1μl aliquot of the fi-
nal reaction sample containing the extension products was 
added to 9μl of Hi-Di formamide (ABI). The mixture 
was then incubated at 95oC for 5 min, placed on ice for 5 
min, and then analyzed by electrophoresis (ABI Prism 
3730 xl DNA analyzer; ABI). The data were analyzed us-
ing GeneMapper software (version 4.0; Applied Biosys-
tems, Carlsbad, CA, USA).
Statistical Analysis
Statistical differences in the genotype distributions and 
allele frequency between patients and controls were tested 
using the chi-square test. Comparisons among BDNF 
Val/Met genotype groups were conducted using the chi- 
square test for categorical data and one-way analysis of 
variance for continuous variables. The level of statistical 
significance was set at p＜0.05. All tests were two-tailed.
RESULTS
The demographic characteristics of the subjects are giv-
en in Table 1. The mean age and education level differed 
significantly between the two groups, but there was no dif-
ference in the gender distribution.
 The BDNF Val66Met polymorphism genotype dis-
tributions and allele frequencies of subjects are presented 
in Table 2. The genotype (χ2=1.33, p=0.52) and allele 
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Table 1. Demographic characteristics of the subjects
Bipolar patients Controls
p value
(n=184) (n=214)
Age (year) 41.51±13.56 23.73±2.51 ＜0.01*
Sex (male/female) 64/120 83/129 0.37†
Education (year) 12.76±4.17 15.53±0.95 ＜0.01*
Values are presented as mean±standard deviation or number. 
*Independent t-test, †chi-square test.
Table 2. BDNF Val66Met polymorphism genotype distributions 
and allele frequencies in bipolar patients and normal controls
Bipolar patients 
(N=184)
Controls 
(N=214)
p value*
Val/Val 66 (35.9) 73 (34.1)
0.515Val/Met 90 (48.9) 99 (46.3)
Met/Met 28 (15.2) 42 (19.6)
Val allele 222 (60.3) 245 (57.2)
0.378
Met allele 146 (39.7) 183 (42.8)
Values are presented as number (%).
*Chi-square test.
Table 3. Differences of clinical variables in BDNF Val66Met 
genotype groups
Val/Val
(n=66)
Val/Met
(n=90)
Met/Met
(n=28)
p value
Age at
 onset (year)
25.57±8.35 30.42±12.91 32.45±13.46 0.037*
Polarity at onset 0.746†
Manic episode 34 (69.4) 46 (63.0) 17 (68.0)
Depressive
 episode
15 (30.6) 27 (37.0) 8 (32.0)
Any psychiatric
 family history 
15 (30.6) 21 (30.0) 5 (21.7) 0.710†
Suicide history 4 (7.4) 10 (13.0) 4 (16.0) 0.461†
Values are presented as mean±standard deviation or number 
(%). *One-way analysis of variance, †chi-square test.
(χ2=0.78, p=0.38) frequencies did not differ significantly 
between the bipolar patients and the normal controls. The 
Val66Met genotype distributions in these two groups 
complied with Hardy-Weinberg equilibrium.
Differences in clinical variables in the various BDNF 
Val66Met genotype groups are presented in Table 3. 
Val/Val, Val/Met, and Met/Met bipolar patient groups did 
not differ significantly with regard to polarity at onset, any 
psychiatric family history, or suicidal history. The only 
clinical feature that did differ significantly among the 
three genotype groups was age at disorder onset.
DISCUSSION
In the present study the allelic and genotypic dis-
tributions of the Val66Met polymorphism of BDNF in bi-
polar disorder were studied with the aim of verifying their 
roles in the genetic susceptibility to bipolar disorder. The 
results provide no support for an association between bi-
polar disorder and the Val66Met polymorphism of BDNF. 
However, we did find a significant association between 
this polymorphism and the age at disorder onset.
The age at the onset of bipolar disorder may be a poten-
tially important marker of a more familial and more severe 
form of the disorder.31) In agreement with our finding, it 
has been reported that bipolar patients with the Val/Val 
genotype experience an earlier onset of the illness (on 
average by 11 years) than those with the Val/Met geno-
type.32) Similarly, Skibinska et al.20) reported a significant 
association with the Val66Met polymorphism in a sub-
group of bipolar patients with early-onset disease, but 
there was no association between the presence of the 
Val66Met polymorphism and bipolar disorder overall. In 
addition, a recent study performed in China demonstrated 
that the frequency of the Val allele in the Val66Met poly-
morphism was significantly increased in the subgroup of 
patients who were younger at the onset of bipolar disor-
der.33) Recent evidence also suggests that decreased 
BDNF gene expression plays a role in the pathophysiol-
ogy of pediatric bipolar disorder.34) Therefore, our results 
suggest that the BDNF gene may be a modifier of age at 
onset of bipolar disorder.
Several genetic studies have shown a significant associ-
ation between the BDNF Val66Met polymorphism and 
several psychiatric disorders.35-37) In patient with schizo-
phrenia, the BDNF Val66Met polymorphism was found to 
be associated with age at onset.38) The Val66Met genotype 
may be involved in the expression of psychiatric pheno-
type in psychiatric disorders by modulating the activity of 
many neurotransmitter systems.4,39,40)
Many studies have analyzed samples of different ethnic 
backgrounds; significant differences in BDNF Val66Met 
genotype frequency have been reported between pop-
ulations from Japan, USA, and Italy.41) There are also re-
ports of allelic or genotypic association between Val66Met 
and bipolar disorder in Caucasians than in other ethnic 
groups, and so the BDNF gene possibly represents a prom-
inent genetic risk factor in this ethnic group. Differences 
in more general genetic backgrounds or local differences 
in and around the BDNF gene may lead to inconsistent re-
sults in different populations.
Our study has several limitations. The first of them is 
the use of multiple comparisons. Although Bonferroni’s 
correction would be more appropriate, this was not ap-
plied since this study was an explorative approach to a ge-
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netically complex trait for which the relationship between 
genotype and phenotype has not been established, and 
thus such corrections might inappropriately increase the 
likelihood that real effects will be missed (type II error 
rates). Second, we did not use structured clinical interview 
for normal control screening. Therefore, it might be possi-
ble that some subjects with psychiatric problems were in-
cluded in control group. However, because this kind of po-
tential misclassification usually decreases the statistical 
power rather than increase, the type I error in this study 
might not be increased. Third, our failure to find a sig-
nificant association between the Val66Met polymorphism 
of BDNF and bipolar disorder may be due to the small 
sample. Fourth, there was significant difference between 
the mean ages of the patient and control groups. The mean 
age of the control group was 23.73 years, and so it is possi-
ble that some members of that group would develop bipo-
lar disorder after the completion of our investigation, 
which may have affected our results. Fifth, we focused on 
single markers that do not cover the entire region of the 
BDNF gene. Two recent genome-wide association studies 
found that four other SNPs were significantly associated 
with bipolar disorder.42,43) Finally, clinical features based 
on retrospective reports are subject to recall bias. 
However, we tried to minimize this bias by obtaining col-
lateral information from all available medical records and 
from interviews with close relatives.
In conclusion, we found no association between the 
Val66Met polymorphism of BDNF and bipolar disorder. 
However, we have shown that the BDNF gene can repre-
sent a genetic risk factor for an earlier onset of bipolar 
disorder. Further investigations with larger samples are 
necessary to confirm the validity of these results. Studies 
designed to increase our understanding of these associa-
tions and to find new candidate genes arising from the ge-
nome-wide association studies are needed.
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